Natixis Makes New $74,000 Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

by · The Markets Daily

https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&h=150&zc=2&src=https://www.marketbeat.com/logos/rigel-pharmaceuticals-inc-logo.png?v=20221216130713
Natixis bought a new position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 57,246 shares of the biotechnology company’s stock, valued at approximately $74,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RIGL. State Street Corp grew its stake in Rigel Pharmaceuticals by 218.2% in the 2nd quarter. State Street Corp now owns 23,945,568 shares of the biotechnology company’s stock worth $27,058,000 after acquiring an additional 16,421,362 shares during the period. Assenagon Asset Management S.A. grew its stake in Rigel Pharmaceuticals by 177.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,624,538 shares of the biotechnology company’s stock worth $4,676,000 after acquiring an additional 2,317,250 shares during the period. Two Sigma Advisers LP grew its stake in Rigel Pharmaceuticals by 517.3% in the 3rd quarter. Two Sigma Advisers LP now owns 1,948,291 shares of the biotechnology company’s stock worth $2,299,000 after acquiring an additional 1,632,700 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in shares of Rigel Pharmaceuticals by 198.6% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,204,420 shares of the biotechnology company’s stock valued at $3,307,000 after buying an additional 1,466,160 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Rigel Pharmaceuticals by 14.0% during the 3rd quarter. Vanguard Group Inc. now owns 11,942,196 shares of the biotechnology company’s stock valued at $14,092,000 after buying an additional 1,463,026 shares during the period. 63.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com downgraded Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th.

Read Our Latest Report on RIGL

Rigel Pharmaceuticals Stock Down 0.9 %

RIGL stock opened at $1.07 on Wednesday. The company has a market cap of $186.58 million, a price-to-earnings ratio of -7.64 and a beta of 0.87. The business has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.17. Rigel Pharmaceuticals, Inc. has a 52 week low of $0.71 and a 52 week high of $2.04.

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. The firm had revenue of $28.13 million for the quarter, compared to analyst estimates of $27.83 million. During the same quarter in the previous year, the company earned ($0.11) earnings per share. As a group, analysts expect that Rigel Pharmaceuticals, Inc. will post -0.19 earnings per share for the current fiscal year.

About Rigel Pharmaceuticals

(Free Report)

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Recommended Stories